H.C. Wainwright Thinks Applied Genetic Technologies’ Stock is Going to Recover

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Applied Genetic Technologies (AGTCResearch Report), with a price target of $24.00. The company’s shares closed last Tuesday at $0.37, close to its 52-week low of $0.35.

According to, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -29.1% and a 21.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Lineage Cell Therapeutics.

Currently, the analyst consensus on Applied Genetic Technologies is a Strong Buy with an average price target of $13.00.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $3.84 and a one-year low of $0.35. Currently, Applied Genetic Technologies has an average volume of 903.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Applied Genetic Technologies Corp. engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.

Read More on AGTC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More